Grape-Seed Pill Extends Mouse Lifespan Up to 64%
A new pill from Lonvi Biosciences, called PCC1, reportedly extended the lifespan of mice by 10-64% in early tests. The supplement, derived from grape-seed extract, is a senolytic designed to clear out dysfunctional "zombie cells" associated with aging.
The foundational research for PCC1 (Procyanidin C1) was published in *Nature Metabolism* in 2021 by scientists from the Shanghai Institute of Nutrition and Health. The study identified the compound after screening nearly 1,000 natural products from plant-derived extracts to find agents that could target senescent cells. PCC1 exhibits a unique dual-action mechanism. At low concentrations, it acts as a senomorphic, calming the inflammatory signals (known as SASP) released by "zombie cells." At higher concentrations, it becomes a true senolytic, selectively triggering apoptosis, or programmed cell death, in those senescent cells while leaving healthy cells unharmed. The widely cited 64% figure refers to the increase in the *remaining* lifespan of very old mice (24-27 months old, equivalent to 75-90 human years) after treatment began. The increase in the mice's total lifespan was 9.4%. Treated mice also showed improved physical fitness. Unlike some first-generation senolytics which have limited tissue penetration, preclinical research suggests PCC1 has a broad-spectrum effect, clearing senescent cells in organs like the lungs, kidneys, liver, and even the retina. This universal activity is attributed to its ability to activate upstream "self-destruct" pathways common to all senescent cells. Shenzhen-based Lonvi Biosciences, led by CEO Yip Tszho (also known as Zico), was established to commercialize this discovery. The company aims to develop a pill that, combined with a healthy lifestyle, could help people live well beyond 100 years. While robust human lifespan trials are yet to be conducted, a small human pilot study with 17 participants aged 50-86 showed measurable reductions in key biomarkers of cellular senescence after just a 3-day course of PCC1. A formal clinical trial is registered to assess PCC1's efficacy for skin rejuvenation, with a study completion date anticipated for late 2024. The natural origin of PCC1 may offer a superior safety profile compared to some synthetic senolytics. For instance, the combination of Dasatinib + Quercetin has been associated with risks like pleural effusion, while another compound, Navitoclax, is known for causing hematologic toxicity. The translation from mouse studies to human efficacy remains a significant hurdle for all longevity research. While the preclinical data is promising, demonstrating both safety and a meaningful impact on healthspan and lifespan in rigorous, large-scale human clinical trials is the critical next step for PCC1.
